Download MendeleyDiscovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo -Active KAT6AB Inhibitor.
Ter Laak, A., Hillig, R.C., Ferrara, S.J., Korr, D., Barak, N., Lienau, P., Herbert, S., Fernandez-Montalvan, A.E., Neuhaus, R., Gorjanacz, M., Puetter, V., Badock, V., Bone, W., Strathdee, C., Siegel, F., Schatz, C., Nowak-Reppel, K., Doehr, O., Gradl, S., Hartung, I.V., Meyerson, M., Bouche, L.(2024) J Med Chem 67: 19282-19303
- PubMed: 39450890
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01709
- Primary Citation of Related Structures:
9FKR - PubMed Abstract:
KAT6A and KAT6B genes are two closely related lysine acetyltransferases that transfer an acetyl group from acetyl coenzyme A (AcCoA) to lysine residues of target histone substrates, hence playing a key role in chromatin regulation. KAT6A and KAT6B genes are frequently amplified in various cancer types. In breast cancer, the 8p11-p12 amplicon occurs in 12-15% of cases, resulting in elevated copy numbers and expression levels of chromatin modifiers like KAT6A. Here, we report the discovery of a new acylsulfonamide-benzofuran series as a novel structural class for KAT6A/B inhibition. These compounds were identified through high-throughput screening and subsequently optimized using molecular modeling and cocrystal structure determination. The final tool compound, BAY-184 ( 29 ), was successfully validated in an in vivo proof-of-concept study.
- Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany.
Organizational Affiliation:
